Article Text

Download PDFPDF

5PSQ-062 Effectiveness of adalimumab in inflammatory bowel disease and influence of response to firstline treatment
  1. MD Gil-Sierra,
  2. MDP Briceño-Casado,
  3. E Rios-Sanchez,
  4. M Dominguez-Cantero,
  5. JM Borrero-Rubio
  1. Hospital Universitario De Puerto Real, Pharmacy, Puerto Real, Spain


Background and importance Adalimumab is an antitumour necrosis factor-α (anti-TNF) agent indicated in ulcerative colitis (UC) and Crohn’s disease (CD). Primary non-response to anti-TNF has been suggested as predictive of poor response to re-treatment with another anti-TNF.

Aim and objectives To assess the effectiveness of adalimumab as the second anti-TNF agent administered, evaluating the influence of response to the first anti-TNF agent.

Material and methods A descriptive retrospective study to July 2019 was conducted. All patients with inflammatory bowel diseases (IBD) treated with adalimumab as the second anti-TNF agent were selected. Variables collected were age, gender, diagnosis, previous anti-TNF therapy, reason for switch, response to anti-TNF, therapy duration and Mayo clinic score (MCS). Effectiveness was measured by MCS at 12, 36 and 60 months. Clinical remission (R) was MCS ≤2 points, clinical response (CR) was a decrease from baseline in MCS ≥3 points and lack of response (LOR) was none of the above. Patients with LOR and treatment suspension in 1 week were considered as LOR in the following weeks. Influence of response to the first anti-TNF agent was evaluated using the relationship between types of response to the first and second treatments. Primary non-response to anti-TNF was defined as LOR after induction of anti-TNF treatment: before week 10 for infliximab and before week 4 for adalimumab. Secondary non-response to anti-TNF treatment was considered as LOR after induction therapy.

Results Fifty-eight patients were included: 39.6% men and 60.4% women. Mean age was 41.6 (86–17) years. Diagnoses: 34.5% UC and 65.5% CD. All patients were pretreated with infliximab (first anti-TNF). Switching to adalimumab was caused by: 2 (3.4%) primary non-response, 45 (77.6%) secondary non-response and 11 (19%) intolerance. Mean adalimumab treatment duration was 29.7 (1–120) months. MCS at 12 months: 43.9% R, 19.3% CR and 36.8% LOR. MCS at 36 months: 29% R, 7.9% CR and 63.1% LOR. MCS at 60 months: 22.9% R, 2.8% CR and 74.3% LOR. One patient with primary non-response to infliximab (1/2, 50%) presented primary non-response to adalimumab; and another with secondary non-response to infliximab (1/45, 2.2%) had primary non-response to adalimumab.

Conclusion and relevance Adalimumab showed long term effectiveness in IBD patients pretreated with another anti-TNF, maintaining >20% of patients in clinical remission at 60 months. Adalimumab’s primary non-response proportion was lower in patients with secondary non-response to a first anti-TNF than in those who had a primary non-response, but studies with larger sample sizes are necessary.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.